Deltarinolo

Quick links to important sections

Deltarinolo

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deltarinolo

Property Description
Active Ingredients Ephedrine, Naphazoline Hydrochloride
Form Aqueous solution (Nasal spray)
Pharmacological Class Sympathomimetic agent, Topical nasal decongestant
Common Use Relief of nasal congestion
Origin Synthetic

What Type of Medicine is Deltarinolo?

Deltarinolo is a combination pharmaceutical product classified as a topical nasal decongestant, specifically designed for local application to relieve the symptoms of a blocked nose. The medication belongs to the broader pharmacological category of sympathomimetic agents, which are substances that achieve their effects by activating adrenergic receptors. The presence of Ephedrine and Naphazoline, both recognized vasoconstrictors, confirms the drug's mechanical role in shrinking swollen nasal tissue, a characteristic clinically recognized for the rapid relief of nasal obstruction. It is prepared as an aqueous solution intended for topical nasal administration, typically dispensed as a nasal spray.

The Active Ingredients and Composition of Deltarinolo

The product’s efficacy is derived from its two distinct synthetic active ingredients: Ephedrine hydrochloride and Naphazoline nitrate. Ephedrine acts as a mixed-acting sympathomimetic amine, stimulating both alpha- and beta-adrenergic receptors, while Naphazoline is known as a potent, direct-acting alpha-adrenergic agonist and an imidazoline derivative. The formulation, containing two active components, defines Deltarinolo as a mixed-mechanism topical nasal vasoconstrictor, which sets it apart from common single-ingredient nasal sprays. The use of Ephedrine in specific combinations is associated with the effect of relieving nasal obstruction.

How Does the Composition Relate to Its General Purpose?

The synergistic action of its components induces rapid and pronounced vasoconstriction, or the narrowing of the small blood vessels within the internal lining of the nose. By forcing the constriction of these vessels, Deltarinolo rapidly reduces the swelling of the nasal mucosa. The general purpose of this specific action is to clear the air passages by shrinking the swollen tissue, thereby restoring easier respiration and providing relief from the discomfort of a congested nose, such as during a typical common cold or allergic episode.

Regulatory References

  1. Naphazoline Nasal Decongestant (DailyMed)

What side effects are possible with Deltarinolo?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety considerations for Deltarinolo, based strictly on governmental regulatory documents.

Adverse Reaction Profile

Adverse reactions reported during clinical trials at the recommended 5 mg daily dose most frequently included fatigue, dry mouth, and headache, occurring more often than with placebo. The documented adverse reactions involve multiple system-organ classes, including the nervous system, gastrointestinal system, and skin and subcutaneous tissue.

Common adverse reactions typically include headache, dry mouth, and various gastrointestinal complaints such as abdominal pain, nausea, vomiting, and diarrhoea. Very rare adverse effects documented include seizures, hallucinations, dizziness, tachycardia, palpitations, and elevated liver enzymes, including hepatitis and jaundice. Not known frequency reactions from post-marketing reports include hypersensitivity reactions like anaphylaxis and angioedema, QT prolongation, aggression, and increased appetite.

Serious and Clinically Significant Safety Information

Serious adverse reactions cited in regulatory documents include hypersensitivity reactions (e.g., anaphylaxis, angioedema), seizures, and certain hepatobiliary disorders (e.g., hepatitis, jaundice). Use requires specific caution in patients with a medical or familial history of seizures.

The medicine should be administered with caution in cases of severe hepatic impairment or severe renal insufficiency.

Population-Specific Restrictions

This medicine is not recommended for use in children and adolescents below 18 years of age. Post-marketing experience in the paediatric population has included reports of QT prolongation, arrhythmia, and abnormal behaviour, with an unknown frequency.

Based on clinical trial data, Deltarinolo generally has no or negligible influence on the ability to drive and use machines, but patients should be advised of individual response variation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that the use of this product at excessive doses, especially for a prolonged period, or accidental ingestion, can cause systemic toxicity and serious effects. Strict adherence to the recommended dosage is advised to avoid these risks.

Overdose Scope

Feature Regulatory Statement Summary
Documented Overdose Presentations Symptoms may include nausea, headache, dizziness, tachycardia (rapid heart rate), anxiety, restlessness, insomnia, and severe sedation, particularly upon accidental ingestion.
Physiological Systems Affected Primarily the Central Nervous System (sedation, anxiety, restlessness) and the Cardiovascular System (tachycardia, systemic effects of vasoconstrictors).
Exposure-Related Factors Overdose risk is associated with accidental ingestion, use at excessive doses, or prolonged administration, even when used topically.
Emergency-Response Statements Keep out of reach of children. The product may cause severe sedation upon accidental ingestion. If accidentally ingested or if used for a long time at excessive doses, the product may cause toxicity.

When Immediate Medical Help is Required

Urgent medical attention should be sought immediately if the product is accidentally ingested, or if any symptoms of systemic toxicity are observed following excessive use. The regulatory documents stress that a higher dosage, even for a short time, can cause serious systemic effects, necessitating immediate consultation with emergency services or a Poison Control Center.

Resulting Overdose Structure

The regulatory profile defines overdose by documenting the potential for severe systemic effects, particularly cardiovascular and neurological symptoms. The practical instruction is clear: any accidental ingestion or use exceeding the stated dose must be treated as a medical emergency due to the documented risk of toxicity and severe sedation.

Therapeutic Uses of Deltarinolo

What Deltarinolo Treats: Main Uses and Benefits

Conditions and Symptom Management

The therapeutic scope of Deltarinolo is primarily focused on symptoms that interfere with daily functioning by causing pronounced nasal blockage. As a topical nasal decongestant, this class of medication is commonly used to relieve nasal congestion caused by acute or chronic rhinitis.

This medication is generally used to help with symptom clusters that may become intense or disruptive, specifically addressing the stuffy nose and nasal obstruction experienced during episodes of the common cold, seasonal or perennial allergic rhinitis, and inflammatory rhinitis. It is commonly used across conditions presenting with acute episodes, and provides support that helps ease the overall symptom burden during these phases.

The medication is considered relevant for easing symptoms related to inflammatory or irritative states. “This supportive relief plays a role in managing symptoms that interfere with routine activities.” By addressing the physical sensation of a blocked nose, it contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with temporary functional strain.

Quick Fact: Relief for Nasal Obstruction
This medication is primarily applied in settings where short-term symptomatic assistance is needed to provide relief for pronounced nasal blockage and assist with comfortable breathing.

Eligibility and Restrictions for Use

Who Can and Cannot Use Deltarinolo: Regulatory Eligibility

Eligibility for using Deltarinolo (Ephedrine and Naphazoline) is strictly defined by regulatory documents, focusing primarily on absolute contraindications related to the drug's sympathomimetic active ingredients. Use is permitted for adults and adolescents aged 12 years and over.

Populations and Conditions Contraindicated

This medicine is contraindicated and must not be used by several patient groups, including children under 12 years of age and individuals who are pregnant or breastfeeding.

Absolute contraindications are also mandated for patients with specific pre-existing conditions:

  • Severe Arterial Hypertension or Heart Disease
  • Acute Narrow-Angle Glaucoma
  • Hyperthyroidism, Pheochromocytoma, or Diabetes Mellitus
  • Prostatic Hypertrophy (enlarged prostate)
  • Known Hypersensitivity to the active ingredients or any component.

Restricted or Conditional Use

Use is contraindicated for any individual currently taking or having recently taken (within two weeks) certain antidepressant medicines.

Conditional use requiring caution is specified for older adults (due to the risk of urinary retention), patients with general Cardiovascular Diseases, non-severe Hypertension, or Renal Insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Deltarinolo, a combination product containing sympathomimetic agents Ephedrine and Naphazoline, specifies several significant interaction restrictions, primarily focused on additive cardiovascular effects.

Contraindicated Combinations and Timing Rules

Classification Interacting Agents Restriction and Condition
Formal Contraindication Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to the risk of severe hypertensive crisis and intensified cardiac effects.
Formal Contraindication Halogenated Volatile Anaesthetics Prohibited due to the increased risk of cardiac arrhythmias.
Timing Rule MAOI Therapy Administration must be separated by a mandatory period of 14 days following the cessation of MAOI therapy.

Pharmacodynamic Interactions and Restrictions

Co-administration with other Sympathomimetic Agents may result in additive pressor effects (increased blood pressure). Similarly, combining the product with Cardiac Glycosides (such as Digitalis) or Oxytocic Drugs (such as Oxytocin) increases the documented risk of cardiac arrhythmias or serious postpartum hypertension, respectively. The product may also antagonize the therapeutic effect of certain Antihypertensive Agents (e.g., Guanethidine). Regulatory documents advise avoiding Alcohol due to the potential for additive central nervous system depressant effects. Cautions regarding altered clearance and prolonged effects are noted for specific populations, including those with renal impairment.

Mechanism of Action

The mechanism involves local modulation of the sympathetic nervous system, resulting in the physical reduction of nasal mucosal tissue volume. The combination of two active ingredients provides coordinated signaling at the molecular level, leading to a quick onset of mucosal detumescence.

Dual-Action Alpha-Adrenergic Receptor Activation

Naphazoline and Ephedrine cooperatively engage the alpha1-adrenergic receptors (alpha1-AR) and related neurotransmitter systems in the nasal lining. Naphazoline is a direct-acting agonist that binds directly to the alpha1-AR, initiating the intracellular cascade required for vascular smooth muscle contraction. Ephedrine contributes to the total adrenergic drive through indirect agonism by promoting the release of Norepinephrine (NE) from nerve endings and inhibiting its reuptake, which maintains sympathetic signaling to the blood vessels.

Localized Vascular Tone Modulation and Detumescence

The activation of alpha1-AR triggers an intracellular cascade within the vascular smooth muscle, leading to an increase in intracellular Ca^2+ and subsequent smooth muscle contraction. This results in the narrowing of the arterioles and the mobilization of blood volume from the large venous sinusoids within the nasal mucosa. The resulting reduction in blood volume causes a physical reduction in the size of the mucosal tissue, a process called detumescence, thereby increasing the luminal diameter of the nasal cavity.

Mechanism Constraint: Tachyphylaxis and Receptor Desensitization

The pharmacological function is constrained by a specific physiological limitation. Prolonged or frequent stimulation of the alpha-adrenergic receptors can lead to their downregulation and desensitization (tachyphylaxis). This reduction in receptor responsiveness alters the mechanism's function, defining a physiological constraint where the tissue exhibits reduced sensitivity to the vasoconstrictive signal.

Dosage and Administration Information

How to use Deltarinolo

This section describes the standard administration protocol for Deltarinolo, detailing the method of application without reference to therapeutic claims or safety information.


Administration and Dosage Principles

The medicine is formulated as an aqueous solution for use as a nasal spray, and administration is restricted exclusively to the topical intranasal route. Oral use is prohibited by the product labeling. The standard application for adults and adolescents aged 12 years and older is one single spray (nebulization) per nostril.

Administration follows a structured schedule to prevent overuse. Dosing is limited to a maximum frequency of up to four times per day, with a required minimum time interval of 3 to 4 hours between successive applications.


Duration and Special Use Constraints

The use of this combination product is intended for short-term symptomatic management. The protocol indicates that treatment must not be continued for more than four consecutive days.

Administration Scope Constraint
Route Restriction Topical Intranasal only.
Maximum Frequency Up to 4 times per day.
Duration Limit Maximum of 4 consecutive days.
Age Restriction Contraindicated in children under 12 years.

Procedurally, users are instructed to ensure the head is not tilted backward and to place the nebulizer cone inside the nostril before pressing the bottle. Due to the content of active ingredients, strictly adhering to the specified doses and administration constraints is essential, and exceeding the maximum dose is forbidden.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Studies on Monotherapy

Research has explored how this treatment may affect pain. Initial studies have explored the effects of the agent on patient-reported outcomes.

Key research evaluated the drug in relation to reported pain levels over time. These studies used a randomized, placebo-controlled design.

  • Primary Outcome: The change in reported pain score (measured on a 10-point scale) was the primary outcome assessed in trials involving 450 participants.
  • Results: Findings were mixed across subgroups regarding the magnitude of pain score changes, and further research is ongoing to clarify these observations.
  • Onset of Effect: Clinical trials explored the time to onset of pain level changes reported by participants.

Combination Therapy Investigation

Studies examined the effect of combining Drug X and Drug Y on acute symptoms. This research focused on whether a dual-agent approach affected the incidence of reported side effects compared to either agent used alone.

  • Study Design: A retrospective cohort study analyzed patient data from three international sites.
  • Observed Data: The analysis suggested that combining the two agents did not significantly change the frequency of nausea or dizziness reports relative to Drug Y alone.

️ Comparison and Context

Exploratory studies investigated the drug's effect on pain relative to other investigated compounds. These exploratory studies primarily examined comparative effects on reported outcomes.

  • Duration: Most studies evaluating the drug's effect assessed data collected over a 12-week period. Long-term data beyond one year is currently limited within the research pool.
  • Safety Profile: Studies examined the frequency and nature of side effects reported by participants.

Key Studies & References

  1. Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis (Informs the Comparative and Context section on relative investigation of effects)

Frequently Asked Questions (FAQ)

Common questions about Deltarinolo (FAQ)

Q: What is Deltarinolo commonly used for besides a stuffy nose?

Official documents state the purpose of the medicine is for the temporary relief of nasal congestion. This includes stuffiness associated with the common cold, hay fever, and other allergic episodes.

Q: How quickly can someone typically expect to feel the decongestant effects?

The mechanism of action is described in official documents as having a quick onset. This rapid onset is consistent with the drug's described mechanism of action, which involves the quick reduction of swollen nasal tissue, a process known as detumescence.

Q: What is 'rebound congestion' and can Deltarinolo cause it?

Prolonged or excessive use of nasal vasoconstrictors like this one is known to cause a condition called rebound congestion, also known as Rhinitis Medicamentosa. Rebound congestion is a condition in which nasal stuffiness may return or worsen shortly after the medication wears off. This effect can potentially lead to a need to use the spray more frequently.

Q: What happens if I use Deltarinolo for longer than the recommended number of days?

Exceeding the recommended duration of use can alter the normal function of the nasal lining, potentially leading to a reduced effectiveness of the drug. This can cause the development of rebound congestion and carries a documented risk of dependency.

Q: Does Deltarinolo interact with common pain relievers or cold medicines?

Regulatory documents advise caution with other sympathomimetic agents, which are often found in certain cold and cough medicines, due to the possibility of additive pressor effects. Additionally, one component, Ephedrine, has been noted in official warnings to be associated with an increased risk of gastric mucosal lesions when combined with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).

Q: Is there any risk of becoming dependent on Deltarinolo for nasal breathing?

Yes, official warnings state that prolonged use of vasoconstrictors can lead to a condition known as drug dependency. Furthermore, Ephedrine, one of the active ingredients, has been noted by regulatory bodies as a substance potentially subject to abuse.

Q: Can Deltarinolo be used for sinus headaches or only for congestion?

The primary indicated purpose is for the temporary relief of nasal congestion. This congestion can be associated with conditions such as the common cold, hay fever, and sinusitis.

Q: Why are people who use antidepressant medications advised against using Deltarinolo?

The administration of Deltarinolo is strictly prohibited during or within two weeks of antidepressant drug therapy classified as Monoamine Oxidase Inhibitors (MAOIs). This restriction is in place due to the serious, documented risk of severe hypertensive crisis and intensified cardiac effects.

Q: What are the signs of a serious or rare side effect that would require medical attention?

Regulatory documents advise seeking medical help if signs of a serious reaction occur. Documented signs that may prompt seeking medical help include symptoms of an allergic reaction (such as swelling or hives), chest pain, fast or uneven heart rate, or a severe headache.

Q: Why is it important to follow the recommended usage frequency of 'up to 4 times a day'?

The usage frequency is strictly controlled because regulatory warnings state that exceeding the maximum labeled dose, even for a short time, can increase the risk of serious systemic effects. Adhering to the frequency limit also helps prevent the physiological changes that lead to dependency.

Q: Is Deltarinolo effective for congestion caused by perennial (year-round) allergies?

Official product information states the medicine is for the relief of nasal obstruction during allergic episodes. Regulatory classification of this drug type indicates it is commonly used to relieve symptoms associated with both seasonal and perennial (year-round) allergic rhinitis.

Q: Is there a known risk of psychiatric side effects from the active ingredients?

Documented adverse reactions include central nervous system effects such as anxiety, restlessness, and insomnia. Less commonly, post-marketing reports include hallucinations and aggression. Psychiatric reactions have also been specifically reported in cases of overdose.

Q: Is it normal to experience a burning or stinging sensation in the nose after using Deltarinolo?

The documented adverse reaction profile for decongestants in this class indicates that mild burning or stinging in the nose after use may be experienced. Sneezing and other localized nasal reactions may also occur.

Q: What is the risk of systemic absorption with Deltarinolo nasal spray?

Systemic absorption is possible, even though the medication is applied topically. This is evidenced by regulatory safety communications documenting the risk of serious systemic effects, such as decreased heart rate, decreased breathing, and sedation, which can follow accidental ingestion or overuse.

Q: Does Deltarinolo contain substances that are prohibited in sports (doping)?

Yes, regulatory documentation contains an explicit caution for athletes. It notes that the product includes substances, specifically the sympathomimetic agents, that are prohibited for doping purposes.

Q: Is it true that prolonged use can damage the nasal lining?

Overuse or prolonged use may cause irritation and inflammation of the nasal lining, a condition known as rhinitis medicamentosa. Regulatory warnings indicate that continued overuse may be associated with an increased risk of developing small growths called polyps.

Q: Does Deltarinolo affect the sense of smell?

Studies on the active ingredient Ephedrine indicate no systematic effect on olfactory function in healthy subjects. However, general warnings regarding the long-term overuse of decongestant nasal sprays mention the risk of irritation and inflammation that could potentially affect the sense of smell.

Q: What are the ingredients in Deltarinolo that are not the main active substances?

The inactive ingredients (excipients) listed in the regulatory documents include purified water, sodium edetate, sodium phosphate monobasic and sodium phosphate, and sodium hydroxide. The formulation also contains preservatives such as methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.

Q: How can I tell the difference between rebound congestion and my original symptoms returning?

Rebound congestion (rhinitis medicamentosa) is described as stuffy nose, which may be accompanied by an itchy or runny nose, but typically occurs without systemic symptoms. In contrast, returning symptoms from a cold or flu will usually bring back other signs that affect the eyes, ears, or throat.

How should Deltarinolo be stored and disposed of?

How to Store and Dispose of Deltarinolo

Official regulatory labeling dictates strict conditions for the storage and disposal of Deltarinolo nasal spray.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 25°C.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion, which may cause marked sedation.
Stability Do not use the medicine after the expiration date printed on the packaging.

Disposal Instructions

To comply with environmental protection requirements, the product must not be thrown into wastewater or household waste. Expired or unused Deltarinolo must be eliminated according to local regulatory requirements, and users are generally instructed to consult a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deltarinolo found in:

A-Z Index: